GeoVax Labs, Inc. — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014; filed March 20, 2015. The filing is an annual report, not a standalone quarterly filing. GeoVax is a clinical-stage biotechnology company with no approved products or product sales; reported revenue is NIH grant income.
Business context and development
The company develops vaccines using a DNA/MVA platform intended to generate non-infectious virus-like particles in vaccinated individuals. Its lead programs are preventive HIV vaccines, HIV therapeutic research, and newly initiated Ebola/Marburg vaccine development. The clade B preventive HIV vaccine completed Phase 2a testing; Ebola/Marburg programs were in preclinical development.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Grant revenue | $882,956 | $2,417,550 |
| Research and development expense | $1,812,969 | $2,914,878 |
| General and administrative expense | $1,807,605 | $1,792,160 |
| Net loss | $(2,733,555) | $(2,284,943) |
| Net loss per share | $(0.10) | $(0.11) |
| Net cash used in operating activities | $(2,250,107) | $(1,694,592) |
| Cash and cash equivalents at year-end | $1,101,651 | $2,513,861 |
| Working capital at year-end | $1,038,472 | $2,385,990 |
| Total assets / stockholders’ equity | $1,333,198 / $1,146,175 | $2,839,576 / $2,527,227 |
There was no product revenue, so conventional product gross margins are not applicable. Grant income is recognized as related costs are incurred. At December 31, 2014, current liabilities were $187,023; the filing reports no committed lines of credit or long-term debt. Contractual obligations totaled approximately $297,000, principally 2015 lease and purchase commitments.
Material changes and unusual items
- Annual grant revenue fell about 63% year over year, largely reflecting lower eligible grant-funded activity. R&D expense fell about 38%, while G&A was broadly stable.
- Despite lower total operating expenses, net loss increased about 20%, as the reduction in grant revenue exceeded expense reductions. Operating cash use increased from 2013.
- Common shares outstanding rose from 23.8 million to 32.0 million during 2014, including warrant exercises and conversions of preferred stock; financing activities provided $873,400 in 2014.
- In February 2015, after year-end, the company raised $3.0 million in gross proceeds through Series C preferred stock and warrants; reported net proceeds were approximately $2.7 million. The preferred stock is convertible at $0.18 per share, and the financing included substantial additional warrant rights that could dilute common shareholders.
- Stock-based compensation was $479,103 in 2014, compared with $402,104 in 2013. The company recorded no income tax expense and maintained a full valuation allowance against deferred tax assets.
Outlook, risks and contingencies
- Management expected year-end cash, available NIH grant funds and the February 2015 financing proceeds to support planned operations through the first quarter of 2016. Additional funding is needed beyond that period; availability and terms are uncertain.
- Management expected a follow-on HIV preventive vaccine study to begin in late 2015, potentially incorporating a protein boost. Ebola/Marburg animal studies were planned for 2015, with human trials targeted for late 2016, subject to funding and research results. Timelines may change.
- The company has a history of losses, an accumulated deficit of approximately $29.8 million, no commercial products, and substantial dependence on grants, external financing, third-party manufacturers and clinical trial organizations. Failure to raise capital could force program delays, reductions or termination.
- All product candidates remain subject to clinical, manufacturing and regulatory risk; none had regulatory approval. The company relies on contract manufacturers and does not have commercial manufacturing, sales or marketing capabilities.
- Potential Emory University license milestones total approximately $3.45 million, contingent on future development and regulatory events; royalties would also apply if products are commercialized. No material legal proceedings were reported.
- The independent auditor gave an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2014; the auditor did not express an opinion on internal control.
Most important facts for investors to verify
- Current cash runway and actual spending versus management’s projected runway through Q1 2016; confirm grant availability and any new funding.
- Terms, conversion adjustments and potential share dilution from the February 2015 Series C financing and related warrants.
- Whether planned HIV follow-on and Ebola/Marburg preclinical milestones occurred, and whether external funding supports later-stage trials.
- Updated clinical and regulatory data, including safety, immunogenicity and the rationale for the proposed HIV protein boost.
- Latest share count, outstanding warrants and preferred-stock conversion exposure; the filing reported 31,950,813 common shares outstanding as of March 20, 2015.